The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

Cancer Policy

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS joins Trump’s drive to use AI to address chronic disease

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

White House regulatory priorities include “aggressive” HHS agenda

Clinical Roundup

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

Retesting with at-home FIT tests is linked to earlier diagnoses, retrospective cohort study finds

Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

In The Clinic
Trials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

Trials & Tribulations
FreeTrials & Tribulations
FreeTrials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account